Krishna Kant

Dr. Krishna Kant

Functional Nanobiomaterials Group at CINBIO, University of Vigo
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
JAJon Ashley
Jon Ashley
Mohammad-Ali ShahbaziMohammad-Ali Shahbazi
Mohammad-Ali Shahbazi
Krishna KantKrishna Kant
Krishna Kant
VCVinayaka Aaydha Chidambara
Vinayaka Aaydha Chidambara
AWAnders Wolff
Anders Wolff
YSYi Sun
Yi Sun

1 April 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
VDVivek Priy Dave
Vivek Priy Dave
TATien Ngo Anh
Tien Ngo Anh
APAnna-Karin Pernestig
Anna-Karin Pernestig
DTDiana Tilevik
Diana Tilevik
Krishna KantKrishna Kant
Krishna Kant
DBDang Duong Bang
Dang Duong Bang

1 January 2010 in Biomaterials
Verified
Journal Article
Closed access
Krasimir VasilevKrasimir Vasilev
Krasimir Vasilev
ZPZihan Poh
Zihan Poh
Krishna KantKrishna Kant
Krishna Kant
JCJoseph Chan
Joseph Chan
AMAndrew Michelmore
Andrew Michelmore
Dusan LosicDusan Losic
Dusan Losic

1 July 2018 in Biotechnology Advances
Verified
Journal Article
Closed access
Krishna KantKrishna Kant
Krishna Kant
Mohammad-Ali ShahbaziMohammad-Ali Shahbazi
Mohammad-Ali Shahbazi
VDVivek Priy Dave
Vivek Priy Dave
TATien Ngo Anh
Tien Ngo Anh
VCVinayaka Aaydha Chidambara
Vinayaka Aaydha Chidambara
AWAnders Wolff
Anders Wolff

1 March 2019 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
VCVinayaka Aaydha Chidambara
Vinayaka Aaydha Chidambara
TATien Ngo Anh
Tien Ngo Anh
Krishna KantKrishna Kant
Krishna Kant
PEPia Engelsmann
Pia Engelsmann
VDVivek P. Dave
Vivek P. Dave
DBDang Duong Bang
Dang Duong Bang

1 April 2024 in Bioactive Materials
Verified
Journal Article
Open access
LILorena Vázquez Iglesias
Lorena Vázquez Iglesias
GCGiovanna Maria Stanfoca Casagrande
Giovanna Maria Stanfoca Casagrande
DGDaniel García-Lojo
Daniel García-Lojo
LLLetícia Ferro Leal
Letícia Ferro Leal
TATien Ngo Anh
Tien Ngo Anh
IPIsabel Pastoriza-Santos
Isabel Pastoriza-Santos
These days, cancer is thought to be more than just one illness, with several complex subtypes that require different screening approaches. These subtypes can be distinguished by the distinct markings left by metabolites, proteins, miRNA, and DNA. Personalized illness management may be possible if cancer is categorized according to its biomarkers. In order to stop cancer from spreading and posing a significant risk to patient survival, early detection and prompt treatment are essential. Traditional cancer screening techniques are tedious, time-consuming, and require expert personnel for analysis. This has led scientists to reevaluate screening methodologies and make use of emerging technologies to achieve better results. Using time and money saving techniques, these methodologies integrate the procedures from sample preparation to detection in small devices with high accuracy and sensitivity. With its proven potential for biomedical use, surface-enhanced Raman scattering (SERS) has been widely used in biosensing applications, particularly in biomarker identification. Consideration was given especially to the potential of SERS as a portable clinical diagnostic tool. The approaches to SERS-based sensing technologies for both invasive and non-invasive samples are reviewed in this article, along with sample preparation techniques and obstacles. Aside from these significant constraints in the detection approach and techniques, the review also takes into account the complexity of biological fluids, the availability of biomarkers, and their sensitivity and selectivity, which are generally lowered. Massive ways to maintain sensing capabilities in clinical samples are being developed recently to get over this restriction. SERS is known to be a reliable diagnostic method for treatment judgments. Nonetheless, there is still room for advancement in terms of portability, creation of diagnostic apps, and interdisciplinary AI-based applications. Therefore, we will outline the current state of technological maturity for SERS-based cancer biomarker detection in this article. The review will meet the demand for reviewing various sample types (invasive and non-invasive) of cancer biomarkers and their detection using SERS. It will also shed light on the growing body of research on portable methods for clinical application and quick cancer detection.